文献速递类风湿关节炎

接受改善病情抗风湿药治疗的类风湿关节炎患者中重组带状疱疹疫苗的免疫原性及其对疾病活动的影响

Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs.
PubMed 文献 · RMD Open · 2024-02-21

这项前瞻性纵向研究纳入53例接受改善病情抗风湿药治疗的类风湿关节炎患者和10名对照,间隔2个月接种两剂重组带状疱疹疫苗。接种后水痘-带状疱疹病毒特异性细胞免疫和体液免疫均显著升高,且未观察到疾病活动指数显著增加或不良事件增多,仅2例(3.8%)出现轻度可控的类风湿关节炎复发。

要点

  • 接种后水痘-带状疱疹病毒特异性细胞免疫和体液免疫较接种前显著升高(p<0.001-0.014)。
  • 三种改善病情抗风湿药治疗组间免疫应答幅度和倍数增长无显著差异。
  • 随访6个月未观察到疾病活动指数显著增加或不良事件增多。

核心结论

  • 重组带状疱疹疫苗在接受改善病情抗风湿药治疗的老年类风湿关节炎患者中具有稳健的免疫原性,且安全性在临床可接受范围内。

研究设计与样本

  • 前瞻性纵向研究,纳入53例年龄≥50岁、接受改善病情抗风湿药治疗的类风湿关节炎患者(传统合成改善病情抗风湿药20例、生物制剂改善病情抗风湿药23例、靶向合成改善病情抗风湿药10例)和10名对照个体。
  • 参与者间隔2个月接受两剂重组带状疱疹疫苗肌肉注射,于首次接种后0和3个月评估水痘-带状疱疹病毒特异性CD4+ T细胞应答和IgG抗体应答。
  • 首次接种后监测6个月的疾病活动度、复发和不良事件。

主要发现

  • 三种改善病情抗风湿药治疗组类风湿关节炎患者接种后水痘-带状疱疹病毒特异性细胞免疫和体液免疫较各自接种前显著升高(p<0.001-0.014)。
  • 三种改善病情抗风湿药治疗组间免疫应答的幅度和倍数增长无显著差异。
  • 传统合成改善病情抗风湿药治疗患者与生物制剂或靶向合成改善病情抗风湿药治疗患者间细胞免疫和体液免疫的疫苗应答率无显著差异。
  • 首次接种后6个月随访期内未观察到疾病活动指数显著增加或不良事件。
  • 重组带状疱疹疫苗诱导的类风湿关节炎复发发生于2例患者(3.8%),但程度轻微且可控。

关键数值与推荐

  • 细胞免疫和体液免疫应答较接种前显著升高,p<0.001-0.014。
  • 三种改善病情抗风湿药治疗组间免疫应答幅度和倍数增长无显著差异。
  • 传统合成改善病情抗风湿药治疗患者与生物制剂或靶向合成改善病情抗风湿药治疗患者间疫苗应答率无显著差异。
  • 类风湿关节炎复发2例(3.8%),程度轻微且可控。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to determine the immunogenicity and the influence on disease activity of an adjuvanted recombinant varicella-zoster virus (VZV) subunit vaccine (RZV) in patients with rheumatoid arthritis (RA) treated with disease-modifying antirheumatic drugs (DMARDs). METHODS: This prospective longitudinal study enrolled 53 patients with RA (aged ≥50 years) treated with DMARDs (conventional synthetic (cs)DMARDs 20, biological (b)DMARDs 23 and targeted synthetic (ts)DMARDs 10) and 10 control individuals. The participants received two intramuscular RZV 2 months apart. VZV-specific CD4+ T cell responses (cell-mediated immunity; CMI) and IgG antibody responses (humoral immunity; HI) were assessed at 0 and 3 months after the first RZV administration using flow cytometry and enzyme immunoassay, respectively. Disease activity (Disease Activity Score 28-C reactive protein and Clinical Disease Activity Index), flares and adverse events were monitored for 6 months after the first vaccination. RESULTS: VZV-specific CMI and HI significantly increased in the three DMARDs-treated patients with RA after RZV administration compared with the corresponding prevaccination values (p<0.001-0.014), and the magnitudes and fold-increases of those responses were not significantly different among the three DMARDs-treated patients with RA. Furthermore, the vaccine response rates of CMI and HI were not significantly different between csDMARDs-treated patients and b-DMARDs or ts-DMARDs-treated patients. Meanwhile, no significant increases in disease activity indices or adverse events were observed in these patients during the 6-month follow-up period after the first vaccination. RZV-induced RA flares occurred in two patients (3.8%) but were mild and controllable. CONCLUSION: RZV is robustly immunogenic and has a clinically acceptable safety profile in elderly patients with RA receiving DMARDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kojima S, Iwamoto T, Kobayashi Y, et al. Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs. RMD Open. 2024. PMID: 38388170. doi:10.1136/rmdopen-2023-003902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。